Analysts at JP Morgan initiated coverage on Juno Therapeutics Inc. JUNO with a Overweight rating.
The target price for Juno Therapeutics is set to $66.
Juno Therapeutics' shares declined 3.59% to $59.30 in pre-market trading.
Market News and Data brought to you by Benzinga APIs© 2024 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
Comments
Loading...
Benzinga simplifies the market for smarter investing
Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.
Join Now: Free!
Already a member?Sign in
